HBK Investments’s Starling Oncology, Inc. Warrant STLNW Stock Holding History
Bought
Maintained
Sold
Other funds holding STLNW
LP
DM
HCM
DKCM
JG
DCM
USPCM
WAM
HBK Investments's STLNW Position: Q1 2022 in Review
HBK Investments sold out of Starling Oncology, Inc. Warrant (STLNW) in Q1 2022, closing a stake of 14,000 shares — an estimated $10K sold.
HBK Investments first reported a position in STLNW in Q4 2021 and held it in 1 quarter. The position peaked at $10K in Q4 2021. 12 funds tracked by Wall St. Rank hold STLNW as of Q1 2022.
- HBK Investments reported no remaining Starling Oncology, Inc. Warrant position as of Q1 2022 after selling out during the quarter.
- HBK Investments sold 14,000 Starling Oncology, Inc. Warrant shares in Q1 2022, an estimated $10K.
- HBK Investments first reported a position in Starling Oncology, Inc. Warrant in Q4 2021 and held it in 1 quarter.
- HBK Investments's Starling Oncology, Inc. Warrant position peaked at $10K in Q4 2021.
- 12 funds tracked by Wall St. Rank held Starling Oncology, Inc. Warrant as of Q1 2022.
Based on HBK Investments's 13F filing for Q1 2022, filed 16 May 2022.